Sentence examples for cruise trial from inspiring English sources

After treatment with ranibizumab in the CRUISE trial (2010 ff). 10 45 46 there were no consistent differences in ocular or systemic adverse events between the intervention groups.

The Central Retinal Vein Occlusion (CRUISE) trial (2010 ff). 10 45 46 compared monthly injections of 0.3 or 0.5 mg of ranibizumab (n=132 and 130) over 6 months with sham injection (n=130).

In the CRUISE trial (2010 ff). 10 45 46 vision-related quality of life (NEI-VFQ) was similarly increased in both ranibizumab groups and statistically significantly more than in the sham group at 6 months (+6.2 compared with +2.8).

Using the standard Bucher [ 19] method to calculate the indirect relative risk, adjusting for the sham treatment, of dexamethasone versus ranibizumab would lead to indirect probabilities of dexamethasone patients achieving selected outcomes in the setting of the CRUISE trial of >1.

With the Bayesian model this was achieved by generating indirect probabilities, i.e., the probabilities we would expect to observe relative to the expected response to the sham treatment if dexamethasone had been used in the ranibizumab BRAVO and CRUISE trial populations.

In the CRUISE trial (2010 ff). 10 45466 mean change in BCVA was significantly increased in the ranibizumab groups (no difference between doses) compared with the sham group at 6 and 12 months (12 letters gained in the 0.5 mg group compared with 7.6 in the sham group).

However, in the BRAVO and CRUISE trials, inflammation occurred less frequently in ranibizumab-treated eyes than in sham-treated eyes [131, 134].

The changes in BCVA from baseline to month 1 for ranibizumab from the BRAVO and CRUISE trials are summarized in Table  1 and published results from the GENEVA trials for dexamethasone in Table  2.

Eventually Frank offered the Liverpudlian a trial cruise across the stormy Wash at night.

After a month's trial cruise in the northern Atlantic, Fram sailed to Kristiansand in late July 1910 to take the dogs on board and to make final preparations for departure.

Both treatments have been shown to be effective against the visual acuity loss that is associated with both diseases, ranibizumab in the BRAVO [ 7] and CRUISE [ 8] trials in BRVO and CRVO, respectively, and dexamethasone implant in the GENEVA trials, two identically designed trials in BRVO and CRVO, from which the results were pooled and published together [ 9– 11].